Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Al-3810
2. E-3810
1. 1058137-23-7
2. E-3810
3. E-3810 Amine
4. E-3810 Free Base
5. Al-3810
6. Pp449xa4bh
7. 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-n-methyl-1-naphthamide
8. Chebi:65209
9. 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-n-methylnaphthalene-1-carboxamide
10. Co-3810
11. S 80881
12. S-80881
13. 1-naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-
14. 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-n-methylnaphthalene-1-carboxamide
15. 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-n-methyl-1-naphthamide
16. Chembl2180605
17. Lucitanib [inn]
18. 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-n-methylnaphthalene-1-carboxamide
19. Lucitanib [usan:inn]
20. Unii-pp449xa4bh
21. Lucitanib(e3810)
22. E-3810; Lucitanib
23. Lucitanib (usan/inn)
24. Lucitanib [usan]
25. Lucitanib [who-dd]
26. Schembl381394
27. Gtpl7649
28. Chembl2220486
29. E 3810;e3810;lucitanib
30. Dtxsid30147356
31. Amy24149
32. Bcp05747
33. Ex-a2052
34. Bdbm50399539
35. Nsc782762
36. Nsc800786
37. Zinc77024213
38. Bcp9000632
39. Cs-0782
40. Db11845
41. Nsc-782762
42. Nsc-800786
43. Sb16928
44. 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide
45. Ncgc00378878-02
46. Ncgc00378878-03
47. Ac-35833
48. As-82279
49. Da-33429
50. Hy-15391
51. Ft-0704073
52. D11762
53. E-3810e-3810
54. Q27082198
55. 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxy-quinolin-4-yloxy)-n-methyl-1-naphthamide
56. 3zc
| Molecular Weight | 443.5 g/mol |
|---|---|
| Molecular Formula | C26H25N3O4 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 443.18450629 g/mol |
| Monoisotopic Mass | 443.18450629 g/mol |
| Topological Polar Surface Area | 95.7 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 686 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
64
PharmaCompass offers a list of Lucitanib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lucitanib manufacturer or Lucitanib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lucitanib manufacturer or Lucitanib supplier.
PharmaCompass also assists you with knowing the Lucitanib API Price utilized in the formulation of products. Lucitanib API Price is not always fixed or binding as the Lucitanib Price is obtained through a variety of data sources. The Lucitanib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lucitanib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lucitanib, including repackagers and relabelers. The FDA regulates Lucitanib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lucitanib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lucitanib supplier is an individual or a company that provides Lucitanib active pharmaceutical ingredient (API) or Lucitanib finished formulations upon request. The Lucitanib suppliers may include Lucitanib API manufacturers, exporters, distributors and traders.
Lucitanib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lucitanib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lucitanib GMP manufacturer or Lucitanib GMP API supplier for your needs.
A Lucitanib CoA (Certificate of Analysis) is a formal document that attests to Lucitanib's compliance with Lucitanib specifications and serves as a tool for batch-level quality control.
Lucitanib CoA mostly includes findings from lab analyses of a specific batch. For each Lucitanib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lucitanib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lucitanib EP), Lucitanib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lucitanib USP).
